Oramed Granted Approval for Phase IIA Diabetic Study
March 19, 2008
Oramed Pharmaceuticals has received approval from the Institutional Review Board committee of Hadassah Medical Center in Jerusalem to conduct a Phase IIA study of its oral insulin on diabetic volunteers.
This Phase IIA study is designed to evaluate the safety and efficacy of Oramed’s oral insulin capsule on Type II diabetic volunteers. This study is slated to begin in the second quarter of 2008. The trials are expected to last several months.
Nadav Kidron, CEO of Oramed, said: “Oramed’s oral insulin aims to revolutionize the current methods of treating diabetes.”